This study is a single-arm, open-label, multicenter, non-randomized phase II clinical study evaluating the efficacy and safety of BL-M09D1 for injection in patients with locally advanced or metastatic gynecological malignancies and other solid tumors.
Voluntarily sign the informed consent form and agree to comply with the protocol requirements;
Female;
Age: ≥18 years and ≤75 years;
Expected survival time ≥3 months;
Use of chemotherapy, targeted therapy, biologic therapy, immunotherapy, etc., within 4 weeks or 5 half-lives prior to the first dose;
History of severe heart disease;
Prolonged QT interval, complete left bundle branch block, or third-degree atrioventricular block;
Active autoimmune disease or inflammatory disease;
Sichuan Baili Pharmaceutical Co., Ltd.
Lead sponsor
Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.
Collaborator